Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs

Akbulut M., ÜRÜN Y.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.145, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 145
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.critrevonc.2019.102822
  • Dergi Adı: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE
  • Anahtar Kelimeler: Cardiovascular disease, Cancer, Drug-drug interaction, TYROSINE-KINASE INHIBITORS, QT INTERVAL PROLONGATION, ANTICANCER AGENTS, CLINICAL-IMPLICATIONS, CANCER-CHEMOTHERAPY, ADVERSE INTERACTION, POLYPEPTIDES 1B1, P-GLYCOPROTEIN, WARFARIN, RISK
  • Ankara Üniversitesi Adresli: Evet

Özet

Cardiovascular diseases (CVD) and cancer are still the leading causes of death. There are many common etiologic factors, especially smoking and obesity. Therefore, it is not uncommon for CVD and cancer to coexist. Drug-drug interactions (DDIs) inevitably occur in this group of patients, where polypharmacy is increasing due to older age and multiple comorbidities. However, multidisciplinary studies, especially close collaboration of medical oncologists and cardiologists, who deals with the diagnosis and treatment of these diseases, awareness and preventive approaches to DDIs may reduce serious morbidity and mortality. In this review, information about the common treatments used in cardiology and oncology and possible DDIs are discussed.